Baird lowered the firm’s price target on Regeneron (REGN) to $587 from $652 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results while noting Eylea missed already bad expectations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $700 from $750 at Wells Fargo
- Evan Seigerman’s Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets
- Regeneron Buy Rating: Navigating Challenges with a Promising Pipeline and Strategic Investments
- Regeneron’s Eylea Challenges Prompt Underperform Rating Amid Market Erosion and FDA Setback
- Regeneron Reports Strong Q1 2025 Financial Results